(Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) applauds the Energy and Commerce Subcommittee on Oversight and Investigations for holding today’s hearing on the important issue of rising insulin prices. “Drugmakers are solely responsible for setting and raising prescription
(Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) issued the following statement today on a new Avalere study, Generic Drugs in Medicare Part D, Trends in Tier Structure and Placement, released by the Association for Accessible Medicines: As the
A recent blog (“Payers and PBMs Profit from Obscure Pharmacy Fees, While Seniors See No Relief in Prescription Costs”) suggests performance-based price concessions are retained by PBMs, restrict the growth of independent pharmacies, and inflate Medicare Part D enrollee’s out-of-pocket costs—unfounded
Main Information On Tadalafil Principle of Action Tadalafil is the main active ingredient of Cialis, one of the most popular drugs for erectile dysfunction (ED) today. This substance is responsible for the effect of Cialis on the male body. How
PBMs: Committed to Helping Patients The Critical Path Forward: Rx Policies to Reduce Patient Costs, Improve Access For America’s pharmacy benefit managers, PBMs, our core mission is to increase access to affordable prescription drugs for all Americans. But more can
(Washington, D.C.) — The Pharmaceutical Supply and Payment Chain Coalition issued the following statement in response to the Administration’s February 24, 2021, Executive Order on America’s Supply Chains. “As representative organizations of America’s pharmaceutical supply and payment chain, including prescription and over-the-counter
Pharmacy benefit companies actively promote the use of generics and biosimilars. Take a look at the data on drug utilization: 90 percent of prescriptions dispensed are generics or biosimilars. During last week’s hearing in the House Oversight Committee, Dr. Rena
A recent white paper (“The Association Between Drug Rebates and List Prices”) narrowly suggests an association between list prices for brand drugs and the rebate practices of pharmacy benefit managers (PBMs) and insurers, despite an underlying methodology that is notably broader
©2024 PCMA. All Rights Reserved.
